We are live on !
Find out more
II
Ishara Investments Portfolio holdings
AUM
$136M
Turnover
52.83%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$106M
AUM Growth
+$18.2M
(+21%)
Cap. Flow
+$13.7M
Cap. Flow % of AUM
Cap. Flow %
13%
Top 10 Holdings %
Top 10 Hldgs %
50.89%
Holding
56
New
18
Increased
10
Reduced
9
Closed
19
Avg Time Held
Equity + Options
0.1
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.1
years
Avg Time Held Equity only
0.1
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$7.08M |
| 2 |
KalVista Pharmaceuticals
KALV
|
+$4.46M |
| 3 |
Vera Therapeutics
VERA
|
+$3.53M |
| 4 |
Arrowhead Research
ARWR
|
+$3.5M |
| 5 |
Verastem
VSTM
|
+$3.39M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$5.4M |
| 2 |
Nuvation Bio
NUVB
|
+$3.58M |
| 3 |
Annexon
ANNX
|
+$3.24M |
| 4 |
BridgeBio Pharma
BBIO
|
+$2.75M |
| 5 |
United Therapeutics
UTHR
|
+$2.68M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.75% |
| 2 | Miscellaneous | 6.25% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Praxis Precision Medicines
PRAX
$6.75B
| $7.27M | 6.88% |
22,550
-17,450
| -44% | -$5.4M |
2025 Q4
1 quarter
|
|
|
2
Axsome Therapeutics
AXSM
$8.23B
| $6.93M | 6.56% |
+41,000
| New | +$7.08M |
2026 Q1
0 quarters
|
|
|
3
PUT
Praxis Precision Medicines
PRAX
$6.75B
| $6.6M | 6.25% |
+20,500
| New | +$6.34M |
2026 Q1
0 quarters
|
|
4
Xeris Biopharma Holdings
XERS
$1.88B
| $5.94M | 5.63% |
1,025,000
+225,000
| +28% | +$1.49M |
2025 Q4
1 quarter
|
|
|
5
DELISTED
KalVista Pharmaceuticals
KALV
| $5.57M | 5.27% |
+276,750
| New | +$4.46M |
2026 Q1
0 quarters
|
|
6
DELISTED
Amicus Therapeutics
FOLD
| $5.34M | 5.05% |
369,000
+9,000
| +3% | +$129K |
2025 Q4
1 quarter
|
|
7
BioMarin Pharmaceuticals
BMRN
$10.6B
| $4.63M | 4.39% |
82,000
-18,000
| -18% | -$1.05M |
2025 Q4
1 quarter
|
|
|
8
Verastem
VSTM
$783M
| $4.35M | 4.11% |
820,000
+550,000
| +204% | +$3.39M |
2025 Q4
1 quarter
|
|
9
Ultragenyx Pharmaceutical
RARE
$1.43B
| $3.65M | 3.46% |
174,250
+124,250
| +249% | +$2.8M |
2025 Q4
1 quarter
|
|
|
10
Arrowhead Research
ARWR
$7.9B
| $3.47M | 3.29% |
+55,350
| New | +$3.5M |
2026 Q1
0 quarters
|
|
11
Vaxcyte
PCVX
$10B
| $3.34M | 3.16% |
57,400
+7,400
| +15% | +$402K |
2025 Q4
1 quarter
|
|
|
12
Vera Therapeutics
VERA
$2.01B
| $3.3M | 3.12% |
+82,000
| New | +$3.53M |
2026 Q1
0 quarters
|
|
13
Travere Therapeutics
TVTX
$4.68B
| $3.29M | 3.11% |
+110,700
| New | +$3.31M |
2026 Q1
0 quarters
|
|
14
MoonLake Immunotherapeutics
MLTX
$813M
| $3.25M | 3.08% |
+174,250
| New | +$2.89M |
2026 Q1
0 quarters
|
|
15
Zentalis Pharmaceuticals
ZNTL
$202M
| $2.88M | 2.72% |
1,230,000
-90,000
| -7% | -$232K |
2025 Q4
1 quarter
|
|
16
Scholar Rock
SRRK
$4.86B
| $2.82M | 2.67% |
+57,400
| New | +$2.57M |
2026 Q1
0 quarters
|
|
17
Acadia Pharmaceuticals
ACAD
$3.29B
| $2.74M | 2.59% |
123,000
-37,000
| -23% | -$884K |
2025 Q4
1 quarter
|
|
18
Ardelyx
ARDX
$798M
| $2.7M | 2.56% |
+451,000
| New | +$2.98M |
2026 Q1
0 quarters
|
|
19
Mineralys Therapeutics
MLYS
$1.79B
| $2.22M | 2.1% |
+82,000
| New | +$2.4M |
2026 Q1
0 quarters
|
|
20
Genmab
GMAB
$22.8B
| $2.2M | 2.08% |
82,000
+12,000
| +17% | +$360K |
2025 Q4
1 quarter
|
|
21
DBV Technologies S.A. American Depositary Shares
DBVT
$569M
| $2.14M | 2.03% |
+102,500
| New | +$2.14M |
2026 Q1
0 quarters
|
|
22
DELISTED
Catalyst Pharmaceutical
CPRX
| $2.03M | 1.92% |
+82,000
| New | +$1.95M |
2026 Q1
0 quarters
|
|
23
Sionna Therapeutics
SION
$176M
| $1.97M | 1.87% |
+49,200
| New | +$1.88M |
2026 Q1
0 quarters
|
|
24
Contineum Therapeutics
CTNM
$266M
| $1.85M | 1.76% |
+142,000
| New | +$1.9M |
2026 Q1
0 quarters
|
|
25
Alnylam Pharmaceuticals
ALNY
$31B
| $1.7M | 1.61% |
+5,125
| New | +$1.74M |
2026 Q1
0 quarters
|
|
Similar funds
SB
WFA
RC
GBFP
KCA
HMS
TH
CWM
Ishara Investments's Q1 2026 Portfolio in Review
As of Q1 2026, Ishara Investments held 56 positions worth $106M, up 21% from $87.5M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Ishara Investments deployed $13.7M of net new capital in Q1 2026, opening 18 new positions and adding to 10 existing holdings. Its largest new stake was Axsome Therapeutics: 41,000 shares worth $6.93M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Praxis Precision Medicines, an estimated $5.4M trimmed.
- Ishara Investments's largest Q1 2026 buy was Axsome Therapeutics: 41,000 shares worth $6.93M.
- Ishara Investments added most to Verastem in Q1 2026, an estimated $3.39M increase.
- Ishara Investments's biggest Q1 2026 reduction was Praxis Precision Medicines, cutting an estimated $5.4M.
- Ishara Investments fully exited Nuvation Bio in Q1 2026, selling an estimated $3.58M.
- Ishara Investments's ten largest holdings make up 51% of its $106M portfolio in Q1 2026.
- Ishara Investments opened 18 new positions and closed 19 in Q1 2026.
- Ishara Investments's portfolio value rose 21% quarter-over-quarter to $106M.
Based on Ishara Investments's 13F filing for Q1 2026, filed 15 May 2026.